Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337526 | 0.82 | TYMP (0.48) | ADORA1 | |
| SCHEMBL4839727 | 0.81 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADAADORA2B | |
| SCHEMBL1888832 | 0.81 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADAADORA2B | |
| SCHEMBL5794230 | 0.81 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL7897993 | 0.81 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL2343062 | 0.81 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL7525475 | 0.80 | ADORA2A (0.66) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL4845331 | 0.80 | LMNA (0.64) | ADORA2AADORA3ADORA1ADAADORA2B | |
| SCHEMBL29135436 | 0.80 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADAADORA2B | |
| SCHEMBL6399921 | 0.80 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADAADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361923-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100151458-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7695902-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7629321-B2 | Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase) | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090198047-A1 | 2'-Modified Oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7432250-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432249-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080032945-A1 | 2'-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-7138517-B2 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1611249-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20020165189-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6399754-B1 | CONTAINING SULFOPHOSPHATE GROUP | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6307040-B1 | MIXED SEQUENCE OLIGONUCLEOTIDE HAVING AT LEAST ONE MODIFIED 2'-DEOXYFURANOSYL MOIETY MODIFIED BY SUBSTITUTION WITH HALO, AZIDO, AMINO, SUBSTITUTED AMINO, HALOMETHYL, CYANATO, HALOALKOXYL, ALKYL SULFIDE OR SULFONATE, NITRATE OR NITRITE | ISIS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6262241-B1 | ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES | ISIS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-0928290-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0928290-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0549615-A4 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0549615-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992003568-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1992-03-05 | — | — | WO | disclosed |